What are the limitations of the eln 2022 aml risk?

While the eln 2022 aml risk is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the eln 2022 aml risk to ensure safe bedside use and optimal diagnostic accuracy.

How does the eln 2022 aml risk compare to other hematology scores?

The eln 2022 aml risk is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the eln 2022 aml risk free to use?

Yes. OpiCalc provides the eln 2022 aml risk completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

ELN 2022 AML Risk Classification

ELN 2022 Consensus: AML genetic risk classification. Select any cytogenetic or molecular abnormalities found at diagnosis. The highest risk category usually dictates the clinical recommendation.

Favorable Markers

Adverse Markers

Genetic/Molecular Factors Not Listed?

Classified as Intermediate Risk

Includes FLT3-ITD without favorable fusions and other mutations not elsewhere specified.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic stratification of adult patients with Acute Myeloid Leukemia (AML) at the time of diagnosis.

Determining the appropriateness of allogeneic stem cell transplantation in CR1.

Standardizing genetic risk assessment across clinical trials and center registrations.

Patient Population

Adult patients with newly diagnosed AML (excluding APL). Primarily validated in patients receiving intensive induction chemotherapy.

When Not to Rely on This Score Alone

Acute Promyelocytic Leukemia (APL / M3) — has separate risk and management protocols.

Pediatric AML — although genetic factors overlap, the prognostic significance of certain mutations (e.g., FLT3-ITD) differs in children.

Patients with significant comorbidities — ELN risk is biological; patient fitness must be assessed separately.

Section 2

Formula & Logic

Favorable Risk

t(8;21)(q22;q22.1); RUNX1-RUNX1T1

inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Mutated NPM1 without FLT3-ITD (or with low AR < 0.5 — note: ELN 2022 updated this)

bZIP in-frame mutated CEBPA

Adverse Risk (Key Updated 2022)

t(9;11)(p21.3;q23.3); MLLT3-KMT2A

t(v;11q23.3); KMT2A rearranged

t(6;9)(p23;q34.1); DEK-NUP214

inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)

-5, del(5q), -7, -17, or abn(17p)

Complex karyotype (≥3 abnormalities)

Mutated TP53 (VAF ≥10%)

Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2

Section 3

Pearls/Pitfalls

What Changed from 2017?

FLT3-ITD: The allelic ratio (AR) is no longer used for categorization. All FLT3-ITD cases (without favorable fusions) are now intermediate-risk, regardless of NPM1 status.

CEBPA: Previously required biallelic mutations; 2022 update only requires in-frame bZIP mutations.

TP53: Now specifically categorized as adverse, particularly with multisomy or complex karyotype.

Myeloid Neoplasia Mutations: Added a refined list of adverse-risk mutations (ASXL1, BCOR, etc.) commonly seen in secondary AML.

Section 4

Evidence Appraisal

Consensus Guidelines

Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN.

Döhner H et al. • Blood. 2022;140(12):1345-1377.

View Source

Section 5

Literature

Development

The European LeukemiaNet (ELN) panel consists of international AML experts. The 2022 recommendations updated the seminal 2010 and 2017 risk systems to reflect the genomic complexity revealed by large-scale sequencing.

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic stratification of adult patients with Acute Myeloid Leukemia (AML) at the time of diagnosis.

Determining the appropriateness of allogeneic stem cell transplantation in CR1.

Standardizing genetic risk assessment across clinical trials and center registrations.

Patient Population

Adult patients with newly diagnosed AML (excluding APL). Primarily validated in patients receiving intensive induction chemotherapy.

When Not to Rely on This Score Alone

Acute Promyelocytic Leukemia (APL / M3) — has separate risk and management protocols.

Pediatric AML — although genetic factors overlap, the prognostic significance of certain mutations (e.g., FLT3-ITD) differs in children.

Patients with significant comorbidities — ELN risk is biological; patient fitness must be assessed separately.

Section 2

Formula & Logic

Favorable Risk

t(8;21)(q22;q22.1); RUNX1-RUNX1T1

inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Mutated NPM1 without FLT3-ITD (or with low AR < 0.5 — note: ELN 2022 updated this)

bZIP in-frame mutated CEBPA

Adverse Risk (Key Updated 2022)

t(9;11)(p21.3;q23.3); MLLT3-KMT2A

t(v;11q23.3); KMT2A rearranged

t(6;9)(p23;q34.1); DEK-NUP214

inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)

-5, del(5q), -7, -17, or abn(17p)

Complex karyotype (≥3 abnormalities)

Mutated TP53 (VAF ≥10%)

Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2

Section 3

Pearls/Pitfalls

What Changed from 2017?

FLT3-ITD: The allelic ratio (AR) is no longer used for categorization. All FLT3-ITD cases (without favorable fusions) are now intermediate-risk, regardless of NPM1 status.

CEBPA: Previously required biallelic mutations; 2022 update only requires in-frame bZIP mutations.

TP53: Now specifically categorized as adverse, particularly with multisomy or complex karyotype.

Myeloid Neoplasia Mutations: Added a refined list of adverse-risk mutations (ASXL1, BCOR, etc.) commonly seen in secondary AML.

Section 4

Evidence Appraisal

Consensus Guidelines

Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN.

Döhner H et al. • Blood. 2022;140(12):1345-1377.

View Source

Section 5

Literature

Development

Last Comprehensive Review: 2026

Related Hematology Tools

HEP Score

HERDOO2 Rule

Vienna Prediction Model

Padua RAM

Antiphospholipid Syndrome Classification

GAPSS

Thrombophilia Screening Eligibility Algorithm

IPSS-R

IPSS-M

WHO 2022 AML Classification Mapper

Have feedback about this calculator?Let us know.

ELN 2022 AML Risk Classification

ELN 2022 Consensus: AML genetic risk classification. Select any cytogenetic or molecular abnormalities found at diagnosis. The highest risk category usually dictates the clinical recommendation.

Favorable Markers

Adverse Markers

Genetic/Molecular Factors Not Listed?

Classified as Intermediate Risk

Includes FLT3-ITD without favorable fusions and other mutations not elsewhere specified.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic stratification of adult patients with Acute Myeloid Leukemia (AML) at the time of diagnosis.

Determining the appropriateness of allogeneic stem cell transplantation in CR1.

Standardizing genetic risk assessment across clinical trials and center registrations.

Patient Population

Adult patients with newly diagnosed AML (excluding APL). Primarily validated in patients receiving intensive induction chemotherapy.

When Not to Rely on This Score Alone

Acute Promyelocytic Leukemia (APL / M3) — has separate risk and management protocols.

Pediatric AML — although genetic factors overlap, the prognostic significance of certain mutations (e.g., FLT3-ITD) differs in children.

Patients with significant comorbidities — ELN risk is biological; patient fitness must be assessed separately.

Section 2

Formula & Logic

Favorable Risk

t(8;21)(q22;q22.1); RUNX1-RUNX1T1

inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Mutated NPM1 without FLT3-ITD (or with low AR < 0.5 — note: ELN 2022 updated this)

bZIP in-frame mutated CEBPA

Adverse Risk (Key Updated 2022)

t(9;11)(p21.3;q23.3); MLLT3-KMT2A

t(v;11q23.3); KMT2A rearranged

t(6;9)(p23;q34.1); DEK-NUP214

inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)

-5, del(5q), -7, -17, or abn(17p)

Complex karyotype (≥3 abnormalities)

Mutated TP53 (VAF ≥10%)

Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2

Section 3

Pearls/Pitfalls

What Changed from 2017?

FLT3-ITD: The allelic ratio (AR) is no longer used for categorization. All FLT3-ITD cases (without favorable fusions) are now intermediate-risk, regardless of NPM1 status.

CEBPA: Previously required biallelic mutations; 2022 update only requires in-frame bZIP mutations.

TP53: Now specifically categorized as adverse, particularly with multisomy or complex karyotype.

Myeloid Neoplasia Mutations: Added a refined list of adverse-risk mutations (ASXL1, BCOR, etc.) commonly seen in secondary AML.

Section 4

Evidence Appraisal

Consensus Guidelines

Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN.

Döhner H et al. • Blood. 2022;140(12):1345-1377.

View Source

Section 5

Literature

Development

Last Comprehensive Review: 2026

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic stratification of adult patients with Acute Myeloid Leukemia (AML) at the time of diagnosis.

Determining the appropriateness of allogeneic stem cell transplantation in CR1.

Standardizing genetic risk assessment across clinical trials and center registrations.

Patient Population

Adult patients with newly diagnosed AML (excluding APL). Primarily validated in patients receiving intensive induction chemotherapy.

When Not to Rely on This Score Alone

Acute Promyelocytic Leukemia (APL / M3) — has separate risk and management protocols.

Pediatric AML — although genetic factors overlap, the prognostic significance of certain mutations (e.g., FLT3-ITD) differs in children.

Patients with significant comorbidities — ELN risk is biological; patient fitness must be assessed separately.

Section 2

Formula & Logic

Favorable Risk

t(8;21)(q22;q22.1); RUNX1-RUNX1T1

inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Mutated NPM1 without FLT3-ITD (or with low AR < 0.5 — note: ELN 2022 updated this)

bZIP in-frame mutated CEBPA

Adverse Risk (Key Updated 2022)

t(9;11)(p21.3;q23.3); MLLT3-KMT2A

t(v;11q23.3); KMT2A rearranged

t(6;9)(p23;q34.1); DEK-NUP214

inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1)

-5, del(5q), -7, -17, or abn(17p)

Complex karyotype (≥3 abnormalities)

Mutated TP53 (VAF ≥10%)

Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2

Section 3

Pearls/Pitfalls

What Changed from 2017?

FLT3-ITD: The allelic ratio (AR) is no longer used for categorization. All FLT3-ITD cases (without favorable fusions) are now intermediate-risk, regardless of NPM1 status.

CEBPA: Previously required biallelic mutations; 2022 update only requires in-frame bZIP mutations.

TP53: Now specifically categorized as adverse, particularly with multisomy or complex karyotype.

Myeloid Neoplasia Mutations: Added a refined list of adverse-risk mutations (ASXL1, BCOR, etc.) commonly seen in secondary AML.

Section 4